GENELUX CORPORATION Restricted Cash, Current
GENELUX CORPORATION (GNLX) had Restricted Cash, Current of $2.00 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments › Restricted Cash and Cash Equivalent, Current
us-gaap:RestrictedCashCurrent · last filed 2026-08-13
- 2026-06-30: Restricted Cash, Current $2.00M.
- 2026-03-31: Restricted Cash, Current $2.00M.
- 2025-09-30: Restricted Cash, Current $1.00M.
| Period end | Restricted Cash, Current |
|---|---|
| 2026-06-30 | $2.00M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $2.00M 10-Q · filed 2026-05-07 |
| 2025-09-30 | $1.00M 10-Q · filed 2025-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |